[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.100.232. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1989

Preoperative Chemotherapy in Advanced Resectable Head and Neck Cancer: Final Report of the Southwest Oncology Group

Author Affiliations

Stanford, Calif

Arch Otolaryngol Head Neck Surg. 1989;115(2):139. doi:10.1001/archotol.1989.01860260013002

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

At the Triological Society section meeting of the combined otolaryngology spring meeting in Palm Beach, Fla, Dr Schuller and colleagues reported on the final report of a prospective, randomized study comparing standard therapy (surgery plus postoperative radiation) with induction chemotherapy, which included the administration of cisplatin, 50 mg/m2 intravenously (IV) on day 1; methotrexate, 40 mg/m2 IV on day 1; bleomycin, 15 U/m2 IV on days 1 and 8; and vincristine sulfate, 2 mg IV on day 1 for three courses, with 21 days between courses, and an additional 21 days after chemotherapy rest, prior to surgery. Of the 175 patients entered into the study, 158 were eligible for the study, and of these, 76 were randomized to receive standard treatment and 82 were randomized to receive chemotherapy. All patients had operable stage III or stage IV epidermoid carcinoma of the head and neck. The overall chemotherapy

First Page Preview View Large
First page PDF preview
First page PDF preview
×